In a week marked by mixed performances across major indices and encouraging economic data, global markets have shown resilience amid light pre-holiday trading. As inflation nears central bank targets in Europe and consumer spending remains robust in the U.S., investors are increasingly focused on identifying undervalued opportunities. In this environment, stocks trading below their intrinsic value present compelling investment prospects. Here, we explore three prime stocks estimated to be trading up to 45.4% below their intrinsic value.

Top 10 Undervalued Stocks Based On Cash Flows

Name Current Price Fair Value (Est) Discount (Est) Amdocs (NasdaqGS:DOX) US$87.01 US$173.82 49.9% EQT (NYSE:EQT) US$32.66 US$65.31 50% Global PMX (TWSE:4551) NT$126.50 NT$252.88 50% Liontrust Asset Management (LSE:LIO) £6.19 £12.36 49.9% Venus Pipes and Tubes (NSEI:VENUSPIPES) ₹2219.20 ₹4431.87 49.9% Sociedad Química y Minera de Chile (NYSE:SQM) US$36.45 US$72.88 50% Dometic Group (OM:DOM) SEK65.40 SEK130.38 49.8% Enphase Energy (NasdaqGM:ENPH) US$112.91 US$225.41 49.9% Manorama Industries (BSE:541974) ₹835.90 ₹1665.51 49.8% Beijing Aosaikang Pharmaceutical (SZSE:002755) CN¥10.92 CN¥21.79 49.9%

Click here to see the full list of 960 stocks from our Undervalued Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Akbank T.A.S

Overview: Akbank T.A.S., with a market cap of TRY316.94 billion, offers a range of banking products and services both in Turkey and internationally through its subsidiaries.

Operations: Revenue segments for Akbank T.A.S. include TRY77.29 billion from Consumer Banking and Private Banking, and TRY88.67 billion from Commercial Banking, Corporate Banking, and SME Banking.

Estimated Discount To Fair Value: 17.5%

Akbank T.A.S. is trading 17.5% below its estimated fair value of TRY74.08, indicating it may be undervalued based on cash flows. Despite a high level of non-performing loans (2.1%), earnings and revenue are forecast to grow significantly above market rates at 35.8% and 34.5% per year, respectively, with a strong return on equity projected at 32.9%. Recent earnings reports show decreased net income but the stock remains undervalued according to discounted cash flow analysis.

The analysis detailed in our Akbank T.A.S growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of Akbank T.A.S. IBSE:AKBNK Discounted Cash Flow as at Sep 2024

Türk Telekomünikasyon Anonim Sirketi

Overview: Türk Telekomünikasyon Anonim Sirketi, along with its subsidiaries, offers integrated telecommunication services in Turkey and has a market cap of TRY176.40 billion.

Operations: The company's revenue segments include Mobile services generating TRY39.88 billion and Fixed-Line services contributing TRY66.09 billion.

Estimated Discount To Fair Value: 45.4%

Türk Telekomünikasyon Anonim Sirketi's earnings grew by 113.8% last year, and despite a recent dip in net income to TRY1.04 billion for Q1 2024, it trades at TRY51.35, significantly below its estimated fair value of TRY94.10. Revenue is forecast to grow faster than the Turkish market at 26.2% annually, with earnings expected to increase by 29.63% per year over the next three years, underscoring potential undervaluation based on cash flows despite interest payment concerns.

According our earnings growth report, there's an indication that Türk Telekomünikasyon Anonim Sirketi might be ready to expand. Click here to discover the nuances of Türk Telekomünikasyon Anonim Sirketi with our detailed financial health report. IBSE:TTKOM Discounted Cash Flow as at Sep 2024

Inspire Medical Systems

Overview: Inspire Medical Systems, Inc. is a medical technology company that develops and commercializes minimally invasive solutions for obstructive sleep apnea (OSA) patients in the United States and internationally, with a market cap of approximately $5.28 billion.

Operations: Revenue Segments (in millions of $): Inspire Medical Systems generates $705.71 million from its Patient Monitoring Equipment segment.

Estimated Discount To Fair Value: 26%

Inspire Medical Systems reported strong earnings for Q2 2024, with US$195.89 million in sales and a net income of US$9.79 million, reversing last year's loss. The company is trading at a significant discount to its estimated fair value of US$266.27 per share, currently priced around US$197.01. Despite high volatility and moderate revenue growth forecasts (16.7% annually), Inspire's profitability outlook remains robust with anticipated annual earnings growth of 44.93%.

Upon reviewing our latest growth report, Inspire Medical Systems' projected financial performance appears quite optimistic. Get an in-depth perspective on Inspire Medical Systems' balance sheet by reading our health report here. NYSE:INSP Discounted Cash Flow as at Sep 2024

Next Steps

Embark on your investment journey to our 960 Undervalued Stocks Based On Cash Flows selection here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Seeking Other Investments?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IBSE:AKBNK IBSE:TTKOM and NYSE:INSP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]